It is said that next 10 years, diseases that were considered incurable will start becoming curable with the advance of cell and gene therapies. But, the process of developing stem cell-based therapeutic products is time-consuming, complex, requiring non-clinical and clinical studies that demands a distinct approach for each product development.
Stempeutics Research has successfully commercialized Stempeucel® for treating Critical Limb Ischemia due to Buerger’s disease and is India’s first Cell Therapy product approved by DCGI with limited marketing in India. Eyestem Research, a research-based bio startup has moved one step closer in finding a treatment for Dry Age-Related Macular Degeneration after successful animal experiments for its flagship product, Eyecyte-RPE (a suspension of Retinal Pigment Epithelium Cells) for treatment of Dry Age-Related Macular Degeneration.
This webinar brings Cell Therapy Researchers and India’s leading Cell Therapy companies who are scaling cell therapy platform to share their experiences towards advancing this therapy which has tremendous potential to transform lives.
ABLE Webinar Invitation on Zoom
Topic: Commercializing Cell Therapy Products in India
When: Friday, 24th June 2022
Time: 03:30 - 05:00 PM
Discussion will be on Current research trends in cell theraphy.
Welcome & Introduction by Mr G S Krishnan, Hon. President, ABLE
Speakers for the webinar are:
1. Prof. Polani B. Seshagiri, Dept. of Molecular Reproduction, Development & Genetics, IISc, Bengaluru
2. Dr. B N Manohar, MD & CEO, Stempeutics Research
3. Dr. (Lt. Col.) Pawan Kumar Gupta, Sr. Vice President - Medical & Regulatory Affairs, Stempeutics Research
4. Dr. Jogin Desai, Founder & CEO, Eyestem Research
5. Dr. Rajani Battu, Co-founder &, Chief Medical Officer, Eyestem Research
Registration link: https://bit.ly/3x0PZrZ
Follow this link to join our WhatsApp group to get regular updates on this webinar https://bit.ly/3N5KdvR